PARIS, May 16, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) has announced key events for the company at EuroPCR 2022, the annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). The event takes place from May 17 to 20 at the Palais des Congrès in Paris.
Among the planned data presentations are a EuroPCR 2022 abstract submission and three late-breaking clinical trials:
Staging of aortic stenosis according to cardiac lesions: evolution and results at two years – On May 17the results of a pooled analysis of patients treated in the PARTNER 2 and 3 trials undergoing catheter or surgical aortic valve replacement (AVR) will be discussed, focusing on the impact of AVR on the progression or regression of cardiac damage extra-valvular and its association with later prognosis.
Transcatheter tricuspid valve repair: one-year results from the CLASP TR study – On May 19, the one-year results of the Edwards PASCAL transcatheter valve repair system will be discussed. The results at one year were previously presented on April 4, 2022at the 71st Annual Scientific Session and Exhibition (ACC.22) at washington d.c., and patient outcomes from the trial demonstrated a significant reduction in tricuspid regurgitation (TR). The Edwards PASCAL Transcatheter Valve Repair System is approved for use in Europe.
TriCLASP post-marketing study: 30-day results – On May 19, the 30-day results of the Edwards PASCAL Transcatheter Valve Repair System will be presented. This will be the first presentation of data from the TriCLASP post-marketing study, which tracks patient outcomes at centers across Europe whose tricuspid valve disease was treated with the Edwards PASCAL system.
Cardioband TR Early Feasibility Study: One-Year Results – On May 19, the one-year results of the Edwards Cardioband Tricuspid Valve Reconstruction System will be discussed. Half-year results were presented in June 2021 at TVT: the Structural Core Summit at Chicagoshowing favorable results at 30 days maintained at six months.
About Edwards Lifesciences
Edwards Lifesciences is the global leader in patient-focused innovations for monitoring structural heart disease and critical care. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on estimates and assumptions made by the company’s management and are believed to be reasonable, although they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to place undue reliance on these forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors detailed in the company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. These documents, together with important information about the safety of our products, are available on Edwards.com.
The Edwards Cardioband System and Edwards PASCAL Systems are intended for professional use where CE marking is accepted. For a list of indications, contraindications, warnings, precautions and adverse events, please refer to the Instructions for Use (visit eifu.edwards.com where applicable). Edwards devices placed on the European market that meet the essential requirements referred to in Article 3 of Directive 93/42/EEC on medical devices bear the CE conformity marking.
In United States INVESTIGATIVE DEVICES. CAUTION: Limited to experimental use in United States. These devices are for experimental use only and are not available for marketing or commercial sale in United States.
Edwards, Edwards Lifesciences, the stylized E logo, Cardioband, CLASP, PARTNER, PASCAL and TriCLASP are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
View original content to download multimedia: https://www.prnewswire.com/news-releases/edwards-announces-key-events-for-europcr-2022-301547659.html
SOURCE Edwards Lifesciences Corporation